1. Zapata-Wainberg G, Ximénez-Carrillo Rico Á, Benavente Fernández L, Masjuan Vallejo J, Gállego Culleré J, Freijó Guerrero MDM, et al. Epidemiology of intracranial haemorrhages associated with vitamin K antagonist oral anticoagulants in Spain: TAC registry. Interv Neurol. 2015;4(1–2):52–8.
2. Rodríguez Campello A, Roquer González J, Gomis Codina M, Munteis Olivas E, Ois Santiago ÁJ, Herraiz Rocamora J. Hemorragia cerebral en pacientes en tratamiento con anticoagulantes orales. Rev Neurol. 2005;40(1):19.
3. Navarro JL, Cesar JM, Fernández MA, Fontcuberta J, Reverter JC, Gol-Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol. 2007;60(12):1226–32.
4. Katz DF, Maddox TM, Turakhia M, Gehi A, O’Brien EC, Lubitz SA, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline-recommended change in Use of the CHADS to the CHA2DS2 -VASc score for thromboemb. Circ Cardiovasc Qual Outcomes. 2017;10:e003476.
5. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016;68:2508–21.